FDA reviewers voice concern about side effects of belatacept

02/25/2010 | Los Angeles Times (tiered subscription model)

Bristol-Myers Squibb's kidney transplant drug belatacept extended survival better than older treatments, FDA reviewers said, but it also appeared to cause a higher rate of severe kidney rejection and neurological disease. A panel of experts is scheduled to evaluate the drug's safety and efficacy next week.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID